2. PROCALCITONIN DYNAMICS ON PATIENTS WITH BACTERIAL PNEUMONIA
Main Article Content
Abstract
Proposes: Procalcitonin (PCT) is used to reduce the time of antibiotic use in patients with infections, especially in patients with sepsis. However, the role of PCT in patients with pneumonia caused by multidrug-resistant bacteria (P-MDR) has not been studied much, especially in Vietnam. Therefore, the project aimed to determine PCT kinetics in patients with bacterial pneumonia.
Research methods: Longitudinal study, we analyzed PCT dynamics in 121 patients with microbiological and clinical findings confirming bacterial pneumonia from January 2023 to October 2023.
Results: There were 65 patients with pneumonia caused by multidrug-resistant bacteria and 56 patients with pneumonia caused by non-multidrug-resistant bacteria (P-nMDR). The five most common agents causing bacterial pneumonia are Klebsiella pneumoniae (32.23%), Acinetobacter baumannii (26.45%), Pseudomonas aeruginosa (22.31%), Staphylococcus aureus (8.26%), and Escherichia coli (5.79%). The average PCT concentration in the P-MDR group was higher than in the P-nMDR group. PCT clearance time in the P-MDR group was 2.13 times slower than the P-nMDR group. 64.46% of patients who had not stopped using antibiotics at the time PCT was below 0.05 ng/ml.
Conclusions: The average PCT concentration in the P-MDR group was higher than in the P-nMDR group. PCT clearance time in the P-MDR group was slower than the P-nMDR group. It is necessary to conduct a randomized controlled clinical trial following this research to monitor PCT dynamics in patient groups such as COPD and bacterial pneumonia in 2024.
Article Details
Keywords
Procalcitonin (PCT) kinetics, multidrug-resistant bacterial pneumonia (P-MDR), nonmultidrug-resistant bacterial pneumonia (P-nMDR), PCT clearance time, antibiotic discontinuation.
References
of sodium selenite administration and
procalcitonin-guided therapy on mortality in
patients with severe sepsis or septic shock:
a randomized clinical trial, JAMA internal
medicine, 176(9):1266-76, 2016.
[2] Evelien de J, Jos AO, Albertus B et al., Efficacy
and safety of procalcitonin guidance in reducing
the duration of antibiotic treatment in critically
ill patients: a randomised, controlled, open-label
trial, The Lancet Infectious Diseases, 16(7):819-
27, 2016.
[3] Scott F, James B, Ryan F et al., Vital signs:
improving antibiotic use among hospitalized
patients, Morbidity and mortality weekly report,
63(9):194, 2014.
[4] Iván H, Eduardo P, Inés S et al., Kinetics of
procalcitonin in infections caused by multidrug
resistant bacteria, MEDICINA (Buenos Aires),
80(6):599-605, 2020.
[5] George K, Jean C, Mark HW, Antibiotic
strategies in the era of multidrug resistance,
Critical Care, 20(1):1-9, 2016.
[6] Despoina K, Thiago L, Christian BB et al.,
Spectrum of practice in the diagnosis of
nosocomial pneumonia in patients requiring
mechanical ventilation in European intensive
care units, Critical care medicine, 37(8):2360-
9, 2009.
[7] GB Liu, XQ Cui, ZB Wang et al., Detection
of serum procalcitonin and hypersensitive
C-reactive protein in patients with pneumonia
and sepsis, Journal of biological regulators
homeostatic agents, 32(5):1165-9, 2018.
[8] Martin JL, Jennifer MF, Elizabeth D et al., The
antibiotic course has had its day, Bmj, 358, 2017.
[9] Jason P, Wang JN, Kay CS et al., Characteristics
and outcomes of culture-negative versus
culture-positive severe sepsis, Critical care,
17(5):1-12, 2013.
[10] Chanu Rhee, Using procalcitonin to guide
antibiotic therapy. Open forum infectious
diseases; 2017: Oxford University Press US.
[11] Chanu R, Michael KM, Thomas MF,
Procalcitonin use in lower respiratory tract
infections, Up-to-date [cited 2019 August 21]
Available from: URL: https://www upto-date
com/contents/procalcitonin-use-in-lower
respiratory-tract-infections, 2019.
[12] Philipp S, Mirjam CC, Robert T et al., Effect
of procalcitonin-based guidelines vs standard
guidelines on antibiotic use in lower respiratory
tract infections: the ProHOSP randomized
controlled trial, Jama, 302(10):1059-66, 2009.
[13] Philipp S, Yannick W, Ramon S et al., Effect
of procalcitonin-guided antibiotic treatment on
mortality in acute respiratory infections: a patient
level meta-analysis, The Lancet infectious
diseases, 18(1):95-107, 2018.
[14] Nguyen Si-Tuan, Hua My Ngoc, Le Duy
Nhat et al., Genomic features, whole-genome
phylogenetic and comparative genomic analysis
of extreme-drug-resistant ventilator-associated
pneumonia Acinetobacter baumannii strain in
a Vietnam hospital, Infection, Genetics and
Evolution, 80:104178, 2020.
[15] Nan Z, Dongmei Z, Yi H, Procalcitonin and
C-reactive protein perform better than the
neutrophil/lymphocyte count ratio in evaluating
hospital acquired pneumonia, BMC Pulmonary
Medicine, 20(1):1-10, 2020.